항체 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 형태별, 프로세스별, 기능성별, 컴포넌트별(-2035년)

Antibodies Market is anticipated to expand from $262.2 billion in 2024 to $764.7 billion by 2034, growing at a CAGR of approximately 11.3%. The Antibodies Market encompasses the development, production, and distribution of antibodies used in therapeutic, diagnostic, and research applications. These proteins, integral to immune response, are harnessed for treating diseases like cancer and autoimmune disorders. Market growth is fueled by advancements in biotechnology, increasing prevalence of chronic diseases, and rising demand for personalized medicine, emphasizing innovation in monoclonal and polyclonal antibody production.

The Antibodies Market is experiencing robust growth, propelled by advancements in biotechnology and increased prevalence of chronic diseases. The monoclonal antibodies segment is the top performer, driven by its specificity and effectiveness in targeted therapies. Within this segment, cancer treatment antibodies lead, owing to their precision in targeting cancer cells. The polyclonal antibodies segment follows, supported by its cost-effectiveness and broader application in research and diagnostics. In the therapeutic application sub-segment, oncology antibodies dominate, benefiting from ongoing innovations and clinical trials. Autoimmune disease antibodies are the second highest performing, as they address a growing need for effective treatment options. Research antibodies are gaining momentum, fueled by expanding research activities in life sciences. Diagnostic antibodies also show promise, particularly in infectious disease testing, as they provide rapid and accurate results. The market's evolution is further influenced by strategic collaborations and technological advancements, enhancing antibody development and production processes.

Market Snapshot:

The antibodies market is characterized by a diverse range of products, with significant attention on innovative launches that enhance therapeutic efficacy. Pricing strategies are influenced by patent expirations and the advent of biosimilars, which are reshaping competitive dynamics. Market share is largely dictated by the ability to innovate and respond to emerging health challenges, particularly in oncology and autoimmune disorders. Companies are investing in research and development to introduce novel monoclonal antibodies, which are gaining traction due to their targeted therapeutic potential. In the realm of competition benchmarking, key players are distinguished by their robust pipelines and strategic partnerships. Regulatory influences remain pivotal, with stringent guidelines dictating market entry and post-market surveillance. The United States and Europe dominate the regulatory landscape, setting high standards for clinical trials and approval processes. Emerging markets are witnessing increased activity, driven by favorable policies and growing healthcare expenditure. The competitive landscape is evolving, with mergers and acquisitions shaping market trajectories and fostering innovation.

Geographical Overview:

The global antibodies market is witnessing robust growth, with distinct dynamics across various regions. North America leads, propelled by advanced healthcare infrastructure and significant R&D investments. The presence of key pharmaceutical players further accelerates market expansion. Europe follows, with a strong focus on innovative antibody therapies and strategic collaborations among biotech firms. The region's regulatory support and emphasis on precision medicine enhance its market prospects. In the Asia Pacific, the market is burgeoning, driven by increasing healthcare expenditure and a growing prevalence of chronic diseases. Emerging economies like China and India are hotspots for antibody research and commercialization. These countries benefit from government initiatives and expanding biopharmaceutical industries. Latin America and the Middle East & Africa are emerging as promising markets. In Latin America, rising healthcare awareness and investments in biotech infrastructure fuel growth. Meanwhile, the Middle East & Africa are recognizing the potential of antibody therapies in addressing unmet medical needs.

Key Trends and Drivers:

The antibodies market is experiencing robust expansion due to several key trends and drivers. One prominent trend is the increasing prevalence of chronic diseases, which is propelling the demand for diagnostic and therapeutic antibodies. As the global population ages, the incidence of conditions such as cancer and autoimmune disorders rises, necessitating advanced treatment solutions. Technological advancements in antibody production and engineering are also shaping the market. Innovations such as bispecific antibodies and antibody-drug conjugates are enhancing treatment efficacy and patient outcomes. These advancements are fostering a competitive landscape where companies strive to develop next-generation antibody therapies. Furthermore, the growing investment in research and development by pharmaceutical companies and research institutions is a critical driver. This investment is leading to the discovery of novel antibodies and expanding the therapeutic potential of existing ones. The emphasis on personalized medicine is also encouraging the development of tailored antibody treatments, aligning with the trend towards precision healthcare. Additionally, the rising demand for biologics and biosimilars is contributing to market growth. As patents for blockbuster biologics expire, the market is witnessing an influx of biosimilar antibodies, offering cost-effective alternatives. This trend is particularly pronounced in emerging markets, where the need for affordable healthcare solutions is paramount.

Restraints and Challenges:

The antibodies market is currently navigating a landscape marked by several significant restraints and challenges. One of the primary challenges is the high cost associated with antibody development and production, which can deter smaller companies from entering the market. Additionally, stringent regulatory requirements and the lengthy approval process can delay product launches and increase operational costs. Intellectual property issues also pose a challenge, as companies must navigate complex patent landscapes that can impede innovation and collaboration. Moreover, the market faces competition from alternative therapeutics such as small molecules and nucleic acid-based therapies, which can offer distinct advantages. Finally, the need for specialized infrastructure and skilled personnel for antibody production and development can limit market expansion, particularly in emerging economies. These challenges collectively impact the growth trajectory and accessibility of the antibodies market.

Key Players:

Abcam, Bio-Rad Laboratories, Cell Signaling Technology, Rockland Immunochemicals, Sino Biological, GenScript, Novus Biologicals, R&D Systems, Santa Cruz Biotechnology, Proteintech Group, PeproTech, ProSci Incorporated, Atlas Antibodies, Creative Diagnostics, RayBiotech, ImmunoReagents, OriGene Technologies, Jackson ImmunoResearch Laboratories, Bethyl Laboratories, Cytiva

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Form
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Functionality
• 2.10 Key Market Highlights by Component

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Polyclonal Antibodies
  • 4.1.3 Recombinant Antibodies
  • 4.1.4 Murine Antibodies
  • 4.1.5 Chimeric Antibodies
  • 4.1.6 Humanized Antibodies
  • 4.1.7 Fully Human Antibodies
  • 4.1.8 Bispecific Antibodies
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Antibodies
  • 4.2.2 Diagnostic Antibodies
  • 4.2.3 Research Antibodies
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Custom Antibody Development
  • 4.3.2 Antibody Production & Purification
  • 4.3.3 Antibody Labeling
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Hybridoma Technology
  • 4.4.2 Phage Display Technology
  • 4.4.3 Transgenic Mouse Technology
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Autoimmune Diseases
  • 4.5.3 Infectious Diseases
  • 4.5.4 Neurological Diseases
  • 4.5.5 Cardiovascular Diseases
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical Companies
  • 4.6.2 Biotechnology Companies
  • 4.6.3 Research Institutes
  • 4.6.4 Diagnostic Laboratories
• 4.7 Market Size & Forecast by Form (2020-2035)
  • 4.7.1 Liquid Antibodies
  • 4.7.2 Lyophilized Antibodies
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 In Vivo
  • 4.8.2 In Vitro
• 4.9 Market Size & Forecast by Functionality (2020-2035)
  • 4.9.1 Blocking Antibodies
  • 4.9.2 Neutralizing Antibodies
• 4.10 Market Size & Forecast by Component (2020-2035)
  • 4.10.1 Heavy Chain
  • 4.10.2 Light Chain
  • 4.10.3 Fab Fragment
  • 4.10.4 Fc Fragment

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Form
    • 5.2.1.8 Process
    • 5.2.1.9 Functionality
    • 5.2.1.10 Component
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Form
    • 5.2.2.8 Process
    • 5.2.2.9 Functionality
    • 5.2.2.10 Component
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Form
    • 5.2.3.8 Process
    • 5.2.3.9 Functionality
    • 5.2.3.10 Component
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Form
    • 5.3.1.8 Process
    • 5.3.1.9 Functionality
    • 5.3.1.10 Component
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Form
    • 5.3.2.8 Process
    • 5.3.2.9 Functionality
    • 5.3.2.10 Component
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Form
    • 5.3.3.8 Process
    • 5.3.3.9 Functionality
    • 5.3.3.10 Component
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Form
    • 5.4.1.8 Process
    • 5.4.1.9 Functionality
    • 5.4.1.10 Component
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Form
    • 5.4.2.8 Process
    • 5.4.2.9 Functionality
    • 5.4.2.10 Component
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Form
    • 5.4.3.8 Process
    • 5.4.3.9 Functionality
    • 5.4.3.10 Component
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Form
    • 5.4.4.8 Process
    • 5.4.4.9 Functionality
    • 5.4.4.10 Component
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Form
    • 5.4.5.8 Process
    • 5.4.5.9 Functionality
    • 5.4.5.10 Component
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Form
    • 5.4.6.8 Process
    • 5.4.6.9 Functionality
    • 5.4.6.10 Component
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Form
    • 5.4.7.8 Process
    • 5.4.7.9 Functionality
    • 5.4.7.10 Component
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Form
    • 5.5.1.8 Process
    • 5.5.1.9 Functionality
    • 5.5.1.10 Component
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Form
    • 5.5.2.8 Process
    • 5.5.2.9 Functionality
    • 5.5.2.10 Component
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Form
    • 5.5.3.8 Process
    • 5.5.3.9 Functionality
    • 5.5.3.10 Component
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Form
    • 5.5.4.8 Process
    • 5.5.4.9 Functionality
    • 5.5.4.10 Component
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Form
    • 5.5.5.8 Process
    • 5.5.5.9 Functionality
    • 5.5.5.10 Component
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Form
    • 5.5.6.8 Process
    • 5.5.6.9 Functionality
    • 5.5.6.10 Component
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Form
    • 5.6.1.8 Process
    • 5.6.1.9 Functionality
    • 5.6.1.10 Component
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Form
    • 5.6.2.8 Process
    • 5.6.2.9 Functionality
    • 5.6.2.10 Component
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Form
    • 5.6.3.8 Process
    • 5.6.3.9 Functionality
    • 5.6.3.10 Component
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Form
    • 5.6.4.8 Process
    • 5.6.4.9 Functionality
    • 5.6.4.10 Component
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Form
    • 5.6.5.8 Process
    • 5.6.5.9 Functionality
    • 5.6.5.10 Component

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Abcam
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Bio-Rad Laboratories
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Cell Signaling Technology
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Rockland Immunochemicals
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Sino Biological
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 GenScript
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Novus Biologicals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 R&D Systems
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Santa Cruz Biotechnology
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Proteintech Group
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 PeproTech
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 ProSci Incorporated
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Atlas Antibodies
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Creative Diagnostics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 RayBiotech
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 ImmunoReagents
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 OriGene Technologies
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Jackson ImmunoResearch Laboratories
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Bethyl Laboratories
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Cytiva
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us